METHOD AND AGENT FOR PREVENTING INTRA- AND POSTOPERATIVE COMPLICATIONS IN PATIENT WITH LUNG CANCER AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE Russian patent published in 2015 - IPC A61K31/536 A61P11/08 A61B17/24 

FIELD: medicine.

SUBSTANCE: method involves a perioperative drug therapy. Spiriva® Respimat® is administered in accordance with the following regimen: at the preoperative stage - in a dose of 2.5 mcg 2 inhalations once a day for 2 weeks; on the day of operation - before general anaesthesia and artificial pulmonary ventilation, in a dose of 2.5 mcg 1 inhalation, and during surgical management 1 inhalation in a dose of 2.5 mcg is used in an operated lung directly through a two-lumen intratracheal tube immediately after ventilation is restored; in the postoperative period - in a dose of 2.5 mcg 2 inhalations once a day for 2 weeks.

EFFECT: optimal clinical course of the perioperative period, more effective treatment by reducing a rate of intra- and postoperative bronchopulmonary complications in the above group of patients.

2 cl, 2 tbl, 1 ex